한빛사논문
- 조회216
고려대학교
Jie Zheng a,1,2, Kyoungmin Park a,2, Jihoon Jang a, Daryeon Son a,b, Junghyun Park a, Jonggun Kim c, Jeong-Eun Yoo c, Seungkwon You a,b, In-Yong Kim d
aDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
bInstitute of Animal Molecular Biotechnology, Korea University, Seoul 02841, Republic of Korea
cInstitute of Regenerative Medicine, SL, Therapeutics Inc., Seoul 02841, Republic of Korea
dCatholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
1Present Address: Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325,000, China.
2These authors contributed equally to this work.
Corresponding authors: Seungkwon You, In-Yong Kim
Abstract
Stem cells are recognized as an important target and tool in regenerative engineering. In this study, we explored the feasibility of engineering amniotic fluid-derived mesenchymal stem cell-secreted molecules (afMSC-SMs) as a versatile bioactive material for skin regenerative medicine applications in a time- and cost-efficient and straightforward manner. afMSC-SMs, obtained in powder form through ethanol precipitation, effectively contributed to preserving the self-renewal capacity and differentiation potential of primary human keratinocytes (pKCs) in a xeno-free environment, offering a potential alternative to traditional culture methods for their long-term in vitro expansion, and allowed them to reconstitute a fully stratified epithelium sheet on human dermal fibroblasts. Furthermore, we demonstrated the flexibility of afMSC-SMs in wound healing and hair regrowth through injectable hydrogel and nanogel-mediated transdermal delivery systems, respectively, expanding the pool of regenerative applications. This cell-free approach may offer several potential advantages, including streamlined manufacturing processes, scalability, controlled formulation, longer shelf lives, and mitigation of risks associated with living cell transplantation. Accordingly, afMSC-SMs could serve as a promising therapeutic toolbox for advancing cell-free regenerative medicine, simplifying their broad applicability in various clinical settings.
논문정보
- Research article
- 2024년 06월 (BRIC 등록일 2024-05-14)
- 국내 연구진
- 의약학 > 재생의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
